Merck KGaA (OTCMKTS:MKGAF – Get Free Report) shares dropped 7.6% on Friday . The stock traded as low as $153.89 and last traded at $153.89. Approximately 8 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 598 shares. The stock had previously closed at $166.6010.
Merck KGaA Stock Down 2.4%
The company has a market cap of $21.02 billion, a price-to-earnings ratio of 24.83 and a beta of 0.96. The company has a current ratio of 1.31, a quick ratio of 0.84 and a debt-to-equity ratio of 0.27. The firm’s fifty day moving average price is $163.93 and its 200-day moving average price is $149.40.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Elefante Mark B bought a new stake in shares of Merck KGaA in the second quarter worth about $617,000. Ames National Corp acquired a new stake in shares of Merck KGaA during the second quarter worth about $1,009,000. Notis McConarty Edward bought a new position in shares of Merck KGaA during the 2nd quarter valued at about $1,304,000. North Star Asset Management Inc. acquired a new position in shares of Merck KGaA in the 2nd quarter valued at approximately $1,411,000. Finally, Pinnacle Holdings LLC bought a new stake in Merck KGaA during the 2nd quarter worth approximately $1,487,000. 0.10% of the stock is owned by institutional investors and hedge funds.
About Merck KGaA
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Further Reading
- Five stocks we like better than Merck KGaA
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
